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In Brief
Super-enhancers are gene-regulatory
elements that determine cell
transcription, development, phenotype,
and oncogenesis but have not been
implicated in host-pathogen interactions.
Zhou and colleagues find that Epstein-
Barr virus transcription factors and virus-
activated NF-kB subunits converge into
super-enhancers in lymphoblastoid cells
to govern key oncogene expression and
cause continuous cell growth.
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Super-enhancers are clusters of gene-regulatory
sites bound by multiple transcription factors that
govern cell transcription, development, phenotype,
and oncogenesis. By examining Epstein-Barr virus
(EBV)-transformed lymphoblastoid cell lines (LCLs),
we identified four EBV oncoproteins and five EBV-
activated NF-kB subunits co-occupying 1,800
enhancer sites. Of these, 187 had markedly higher
and broader histone H3K27ac signals, characteristic
of super-enhancers, and were designated ‘‘EBV
super-enhancers.’’ EBV super-enhancer-associated
genes included the MYC and BCL2 oncogenes,
which enable LCL proliferation and survival. EBV su-
per-enhancers were enriched for B cell transcription
factor motifs and had high co-occupancy of STAT5
and NFAT transcription factors (TFs). EBV super-
enhancer-associated genes were more highly ex-
pressed than other LCL genes. Disrupting EBV
super-enhancers by the bromodomain inhibitor JQ1
or conditionally inactivating an EBV oncoprotein or
NF-kB decreased MYC or BCL2 expression and ar-
rested LCL growth. These findings provide insight
into mechanisms of EBV-induced lymphoprolifera-
tion and identify potential therapeutic interventions.
INTRODUCTION
Epstein-Barr virus (EBV), the first human tumor virus, discovered
50 years ago in African Burkitt’s lymphoma cells (Epstein et al.,
1964), is causally associated with infectious mononucleosis,
Burkitt’s lymphoma, Hodgkin’s lymphoma, HIV-related lym-
phomas, posttransplant lymphoproliferative diseases (PTLDs),
nasopharyngeal carcinoma, and some gastric cancers (Long-
necker et al., 2013; Young and Rickinson, 2004). In primary
EBV infection, virus transits across the oropharyngeal epithelium
to reach the B cell compartment. EBV converts primary B cells
into activated blasts, which enable EBV to colonize the B cell
compartment. Indeed, EBV-transformed lymphoblasts can beCell Host &seen transiently in patients with infectiousmononucleosis, which
is caused by primary EBV infection (Kurth et al., 2000). Although
T- and NK-cell surveillance eventually contains lymphoblast pro-
liferation, EBV latently infected B cells are the reservoir from
which the virus establishes lifelong infection. With HIV infection,
organ transplantation, or primary immunodeficiency, impaired
control of EBV latently infected B cells leads to fatal lymphopro-
liferative diseases and lymphomas. In vitro, EBV transforms pri-
mary resting B lymphocytes (RBLs) to continuously proliferating
lymphoblastoid cell lines (LCLs). LCLs express the same viral
genes as some EBV lymphomas. These viral genes include six
Epstein-Barr virus nuclear antigens (EBNAs), three latent mem-
brane proteins (LMPs), and multiple microRNAs (Longnecker
et al., 2013; Young and Rickinson, 2004). LCLs are therefore a
useful model for studying EBV mediated B-lymphoid oncogen-
esis (Longnecker et al., 2013).
Reverse genetic studies indicate that viral oncoproteins
EBNA2, EBNALP, EBNA3A, EBNA3C, and LMP1 are each
required for LCL growth and survival (Longnecker et al., 2013).
EBNAs bind to virus and cell DNA through their interactions
with cell DNA binding proteins. EBNA2 and EBNALP are the first
EBV genes expressed after B cell infection (Alfieri et al., 1991).
EBNA2 mostly binds to DNA through the cell DNA binding
protein RBPJ, and activates cell gene transcription, including
MYC, the EBV cell surface receptor CD21, andCD23 (Grossman
et al., 1994; Henkel et al., 1994; Kaiser et al., 1999; Wang et al.,
1987; Zhao et al., 2011b). EBNA2 binds to B cell enhancer
sites 428 kb and 525 kb upstream of MYC and loops to the
MYC TSS to activate MYC transcription (Zhao et al., 2011b).
The EBNA2 C-terminal acidic activation domain recruits basal
and activation-related TFs, including Pol II, p300/CBP, TFIID,
and TFIIH (Tong et al., 1995; Wang et al., 2000). EBNALP coac-
tivates with EBNA2 and derepresses transcription by removing
NCoR and associated repressors from promoter DNA (Harada
and Kieff, 1997; Portal et al., 2006, 2011, 2013). EBNA3A and
EBNA3C repress p16INK4A and p14ARF expression, thereby pre-
venting senescence and enabling continuous LCL growth
(Maruo et al., 2011; Skalska et al., 2013). EBNA3A and EBNA3C
also affect the expression ofmany host genes (Hertle et al., 2009;
Zhao et al., 2011a). However, the growth-inhibiting effects of
EBNA3A or EBNA3C deficiency can only be rescued by restoring
EBNA3A or EBNA3C expression (Maruo et al., 2005, 2006),
indicating that they both have unique nonredundant functions.Microbe 17, 205–216, February 11, 2015 ª2015 Elsevier Inc. 205
LMP1 constitutively activates NF-kB to promote growth and
survival. NF-kBs are dimeric TFs assembled from the RelA,
RelB, cRel, p50, and p52 subunits. In resting B cells, NF-kB is
tethered in the cytosol by IkBa. In LCLs, LMP1 signaling triggers
IkBa degradation and NF-kB homo- or heterodimer nuclear
translocation. Inducible overexpression of a nondegradable
IkBa blocks NF-kB activity and causes LCL apoptosis (Cahir-
McFarland et al., 2000, 2004). Conditional inactivation of
EBNA2, EBNA3A, EBNA3C, or NF-kB identified cell genes
regulated by these EBV oncoproteins. However, only a limited
repertoire of cell genes are coregulated by EBNAs or NF-kB
(Cahir-McFarland et al., 2004; Hertle et al., 2009; Zhao et al.,
2006, 2011a).
Super-enhancers are recently discovered enhancers with
extraordinarily high and broad ChIP-seq signals for activation-
related TFs, H3K27ac modification, bromodomain binding
protein, BRD4, or mediator Med1 (Chapuy et al., 2013; Hnisz
et al., 2013; Love´n et al., 2013; Parker et al., 2013; Whyte
et al., 2013). Super-enhancers are principle determinants of
cell identity and oncogenesis, although a super-enhancer role
in host-pathogen interactions has not yet been reported. Su-
per-enhancers are associated with genes critical for cell func-
tion, are co-occupied by multiple TFs in dense clusters, and
are more sensitive to perturbation than typical enhancers (Cha-
puy et al., 2013; Hnisz et al., 2013; Love´n et al., 2013; Whyte
et al., 2013). Super-enhancer formation can also be rapidly
induced de novo upon cytokine stimulation accompanied by
the decommission of parental cell super-enhancers (Brown
et al., 2014). BRD4 inhibition by bromodomain inhibitor JQ1
has significantly larger effects on super-enhancer-associated
gene expression than on typical enhancer-associated gene
expression (Hnisz et al., 2013; Love´n et al., 2013). In multiple
myeloma (Love´n et al., 2013) and diffuse large B cell lymphomas
(DLBCLs) (Chapuy et al., 2013), theMYC oncogene is controlled
by super-enhancers.
We have now used EBNA2; EBNALP; EBNA3A; EBNA3C; NF-
kB subunits RelA, RelB, cRel, p50, and p52; and ENCODE
GM12878 LCL TF ChIP-seq data for integrated analyses of
EBV super-enhancer effects on LCL growth. We were surprised
to find all four oncogenic EBNAs and all five NF-kB subunits
co-occupying 187 sites that had extraordinarily high H3K27ac
signals, indicative of super-enhancers. As characteristic of su-
per-enhancers, EBV super-enhancers regulated key B cell
growth and survival genes, and super-enhancer disruption by
the BRD4 inhibitor JQ1, or by EBNA2 or NF-kB inactivation, in-
hibited EBV super-enhancer-associated gene expression and
LCL growth.
RESULTS
EBNA2 Super-enhancers
Markedly elevated ChIP-seq signals of the B cell master TF SPI1/
PU.1 distinguish B cell super-enhancers from typical enhancers
(Whyte et al., 2013). Interestingly, we previously found that
LCL EBNA2 sites were enriched for the SPI1 motif, and were
frequently co-occupied by SPI1, suggesting possible EBNA2
incorporation into super-enhancers (Zhao et al., 2011b).
EBNA2 ChIP-Seq signals were therefore tested for hallmarks
of super-enhancer formation (Whyte et al., 2013). Model-based206 Cell Host & Microbe 17, 205–216, February 11, 2015 ª2015 Elseanalysis of ChIP-Seq (MACS) identified 42,251 EBNA2 sites
with p < 105 (Zhang et al., 2008). Many EBNA2 sites were in
broad clusters, characteristic of super-enhancers. EBNA2 sites
within 12.5 kb windows were then merged into 16,133 EBNA2
clusters (Whyte et al., 2013) and ranked by their EBNA2 ChIP-
Seq signal. Interestingly, 888 (5.5%) of the EBNA2 sites had
ChIP-seq signals 23 times higher than typical EBNA2 sites and
were >4 kbwide (see Table S1 available online; Figure 1A). These
sites were therefore subsequently referred to as EBNA2 super-
enhancers.
As expected, most EBNA2 super-enhancers were not near
transcription start sites (TSSs) (Zhao et al., 2011b). We first as-
signed EBNA2 super-enhancers to their nearest genes (Whyte
et al., 2013). Chromatin conformation capture (3C) followed
by deep sequencing (Hi-C) captures long-range enhancer-pro-
moter interactions and defines genome topological association
domains (TADs) (Lieberman-Aiden et al., 2009). We tested our
EBNA2 super-enhancer-associated gene assignments using
high-resolution GM12878 LCL Hi-C data (Selvaraj et al., 2013).
Approximately 86%of EBNA2super-enhancers and their associ-
atedgenepairs occurredwithin the sameHi-CTAD, in agreement
with super-enhancers and their targeted genes frequently co-
occurring within CTCF/Cohesin domains (Dowen et al., 2014).
EBNA2 super-enhancers frequently localized near genes en-
coding relevant B cell TFs, including MYC, MAX, EBF, RUNX3,
ETS1, and BATF, as well as the B cell-specific coactivator
OCAB (Figure 1A). Many other cell TFs, including BATF, EBF,
ETS1, IRF4, SPI1, NFAT, STAT5, and PAX5, co-occupied
EBNA2 super-enhancer sites. RBPJ also had significant signals
at these sites. Cell TFs involved in chromatin looping, such as
CTCF, SMC3, and RAD21, were at adjacent sites (Figure 1B).
EBNA2 upregulation of MYC is essential for LCL growth (Fau-
mont et al., 2009). EBNA2 super-enhancers at 525 kb and
428 kb of the MYC TSS likely induce MYC expression (Alfieri
et al., 1991; Kaiser et al., 1999; Zhao et al., 2011b) (Figure 1B).
The 428 kb EBNA2 super-enhancer site loops to the MYC
TSS in an EBNA2-dependent manner by fluorescence in situ
hybridization (FISH) and 3C-qPCR (Zhao et al., 2011b). MYC
heterodimerizes with MAX to activate Cyclin D2 expression,
promote cell cycle entry, and enable LCL DNA replication. Two
EBNA2 super-enhancer sites also localized near MAX and likely
affect MAX expression (Figure 1A). EBNA2 also upregulates
RUNX3 expression and represses RUNX1 expression (Spender
et al., 1999).
The 888 EBNA2 super-enhancer sites (SE in Figure 1C) had
much higher H3K27ac andH3K4me1 signals than EBNA2 typical
enhancer (TE) sites, indicative of a higher transcription activation
state (Figure 1C).
EBV Super-enhancers
EBNA2 and EBNA3C colocalize at MYC enhancers, with RelA
and EBNALP (Jiang et al., 2014; Portal et al., 2013; Zhao et al.,
2011b, 2014). EBNA3A, RelB, cREL, p50, and p52 binding at
EBNA2 MYC super-enhancers was evaluated. Surprisingly, all
oncogenic EBNAs and NF-kB subunits were at the MYC
enhancer site (Figure 2A). We therefore searched for genome-
wide co-occurrences of all EBNAs and NF-kB subunits. In total,
1,771 sites had significant signals for all EBNAs and NF-kB sub-
units, and were therefore designated as EBV enhancers.vier Inc.
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Figure 1. EBNA2 Super-Enhancers
(A) Rank order of EBNA2 ChIP-seq signals for all EBNA2 sites. Overall, 888 EBNA2 super-enhancer sites have >23-fold higher ChIP-seq signals than the average
signals at 17,000 other EBNA2 sites. These EBNA2 super-enhancer sites are annotated to their nearest cell gene. EBNA2 super-enhancer-associated cell
genes particularly important for LCL growth or survival are indicated.
(B) EBNA2, other TFs, and histone modification ChIP-seq signals at super-enhancers near the MYC locus are shown. Numbers near gene names indicate tag
density. A red arrow indicates theMYC TSS. Magnified views of EBNA2 super-enhancers (525 and 428 kb) ofMYC are shown (black arrows and red boxes).
(C) Average ChIP-seq signals for H3K27ac and H3K4me1 in 80 kb windows around EBNA2 super and typical enhancers are shown. Red indicates EBNA2 super-
enhancers, and blue indicates typical enhancers.
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Since unusually high and broad H3K27ac signals are indica-
tive of super-enhancers, EBV enhancers were ranked based
on their H3K27ac signals. Overall, 187 EBV enhancers had >4-
fold higher H3K27ac signals than the rest of the EBV enhancers.
These were therefore designated as ‘‘EBV super-enhancers’’
(Figure 2B; Table S2). In contrast to typical enhancers, which
had average H3K27ac signals flanking a TF binding site without
central elevation, the H3K27ac signals at EBV super-enhancer
sites were broad and further elevated at the center of TF binding
sites (Figure 2C).
In addition to H3K27ac, EBV super-enhancers also had much
higher signals than typical enhancers for histone modifications,
chromatin remodeling proteins, and basal transcription machin-
ery, including H3K4me1 (3-fold), BRD4 (4.4-fold), Pol II (4.2-fold),
BCLAF (3.6-fold), CHD1 (3.9-fold), MTA3 (3.8-fold), PML (4-fold),
TAF1 (3.1-fold), and WHIP (3.9-fold) (Figures 2C and S1), pro-
teins indicative of high super-enhancer transcription activity.
EBV Super-enhancer-Associated Genes Are Important
for LCL Growth and Survival
EBV super-enhancers were assigned to their target genes by
proximity. A total of 96%of EBV super-enhancers and their regu-
lated gene pairs resided within the same GM12878 LCL Hi-C
TAD (Selvaraj et al., 2013). EBV super-enhancer-associated
genes included IGLL5, MYC, RUNX3, IKZF3/AIOLOS, ETS1,
OCAB, andBCL2 (Figures 2B and 2D). IGLL5 encodes Igl, which
has the strongest super-enhancer in myeloma cells (Love´n et al.,
2013). OCAB is also controlled by a super-enhancer in DLBCLs
(Chapuy et al., 2013), whereas IKZF3 is an IKAROS family B cell
TF that regulates B-cell proliferation. NF-kB-induced BCL2
blocks apoptosis (Henderson et al., 1991). EBV super-enhancers
were also associated with three miRNAs that are highly ex-
pressed in LCLs, including oncomir MIR155, MIR21, and LET7I
(Figure 2B) (Skalsky et al., 2012).
Pathway enrichment analyses for EBV super-enhancer-asso-
ciated genes identified enrichment for apoptosis, DNA damage
response, and MAPK signaling pathways (Table S3).
EBV typical enhancer-associated genes included TCF3/E2A,
EBF, REL, IKZF1/IKAROS, BATF, and IRF4, TFs important for
B cell-specific transcription and B cell identity.
EBV Super-Enhancer Enriched Motifs and Co-occurring
Cell TFs
Super-enhancers are frequently enriched for cell type-specific TF
motifs (Whyte et al., 2013). Similarly, EBV super-enhancers were
significantly enriched for B cell-specific TF motifs, compared to
the other control enhancers which were co-occupied by at least
one EBV TF or NF-kB subunit but less than all nine. Enriched
motifs included MYC, SPI1, ETS1, STAT5, IRF4, RUNX, NFAT,Figure 2. EBV Super-Enhancers
EBV super-enhancers are defined by high H3K27ac signals and the presence of
(A) EBNA2, EBNALP, EBNA3A, EBNA3C, NF-kB subunits RelA, RelB, cRel, p50
of MYC.
(B) A total of 1,771 sites with significant EBV oncoproteins and NF-kB subunit bin
4-fold higher H3K27ac signals than EBV typical enhancers are annotated to thei
(C) Anchor plots for H3K27ac, BRD4, and Pol II show substantially higher and broa
enhancers.
(D) ChIP-seq signals for virus and cell TFs and histone modifications at the BCL2
Cell Host &EBF, E2A, and SPI1/IRF4 composite site (p < 1045) (Figure 3A).
These motifs were also enriched when compared with EBV
typical enhancers (p < 105). Even thoughmany cell type-specific
TFmotifs are enriched in super-enhancers, only a smaller number
of TFs distinguish super-enhancers from typical enhancers
(Whyte et al., 2013). For example, E2A signals distinguish B cell
super-enhancers from typical enhancers (Whyte et al., 2013). In
LCLs, NFAT and STAT5 signals at EBV super-enhancers
were 5.1- and 3.8-fold higher than at typical enhancers (p <
2 3 1016) (Figure 3B). NFAT is implicated in B cell lymphomas
(Pham et al., 2010), whereas STAT5 is constitutively active in
LCLs (Weber-Nordt et al., 1996). STAT5 is also important for
maintaining IL7 levels, which are critical for B cell development
and survival (Clark et al., 2014). Enrichment for these TFs
in EBV super-enhancers likely contributes to super-enhancer
formation and function. Notably, YY1 signals at EBV super-
enhancers were 2.8-fold higher than at typical enhancers (p <
13 1016) (Figure 3B). YY1 is important for long-range chromatin
looping and transcription (Atchison, 2014). YY1 motifs were only
moderately enriched at EBV super-enhancer sites (p < 105), and
only 11% of EBV super-enhancers had YY1 motifs. Therefore,
increased YY1 binding at EBV super-enhancers was likely
through interaction with other DNA binding proteins. EBV su-
per-enhancers were also highly co-occupied by important B
cell TFs, including EBF (100%), BATF (100%), SPI1 (92%),
PAX5 (99%), ETS1 (100%), and IRF4 (100%) (Figures 3B and 3C).
Comparison of EBNA and NF-kB Signals at EBV
Super-Enhancers and Typical Enhancers
ChIP-seq signals for EBNA2, EBNALP, EBNA3A, EBNA3C, and
NF-kB subunits at EBV super-enhancers were compared to
typical enhancers. EBNA2 signals at super-enhancers were
3.6-fold higher than at typical enhancers (p < 7.3 3 1012) (Fig-
ure 3D), whereas ChIP-seq signals for other EBV TFs or NF-kB
subunits were far less significantly different or even similar
between EBV super-enhancers and typical enhancers.
As expected, RBPJ motifs were also enriched (p < 1028)
at EBV super-enhancer sites, and RBPJ signals at EBV super-
enhancer sites were 3.6-fold higher than at typical enhancers
(p < 1.4 3 1010) (Figure 3D). EBNA2 can increase RBPJ DNA
binding (Portal et al., 2011).
EBV Super-Enhancer-Associated Genes Are Expressed
at Significantly Higher Levels Than Typical Enhancer-
Associated Genes
Expression levels of super-enhancer-associatedgenes arehigher
than typical enhancer-associated genes (Whyte et al., 2013). We
therefore compared expression levels of EBV super-enhancer-
associated genes with typical enhancer-associated genesall EBNAs and NF-kB subunits.
, and p52 are all significantly present at the EBNA2 super-enhancer 525 kb
ding are ranked by H3K27ac signals. A total of 187 EBV super-enhancers with
r nearest genes. Genes important for LCL growth and survival are indicated.
der signals (normalized coverage) at EBV super-enhancers than at EBV typical
locus.
Microbe 17, 205–216, February 11, 2015 ª2015 Elsevier Inc. 209
NFAT STAT5 YY1 SPI1
TCF3 ETS1 MYC EBF1
1.2
0.8
0.4
0
1.2
0.8
0.4
0 0
0.5
1.0
1.5
0
1
2
0
0.5
1.0
0
1.0
2.0
-0.1 0
1
2
3
0.1
0.3
0.5
3.01.5
NFAT STAT5 YY1 SPI1
TCF3 ETS1 MYC EBF1
4
3
2
4
3
2
1
2
6
10
2
6
10
2
4
6
8
15
10
5 0.4 5
10
15
0.8
1.2
SE
TE
TF Motif p-value
MYC
SPI1
ETS1
STAT5
IRF4
RUNX
NFAT
EBF1
E2A
SPI1/IRF4
1.0 x 10-62
1.0 x 10-61
1.0 x 10-58
1.0 x 10-58
1.0 x 10-53
1.0 x 10-53
1.0 x 10-50
1.0 x 10-50
1.0 x 10-45
1.0 x 10-43
-4 kb +4 kb
EBNA2
4
2
0
RBPJ
5
3
1
EBNA3A
1.5
1.0
0
0.5
D
C
B
A
C
hI
P-
Se
q 
D
en
si
ty
C
hI
P-
Se
q 
C
ov
er
ag
e
C
hI
P-
Se
q 
D
en
si
ty
*
*
* *
*
*
* * *
denotes p < 1 x 10-6
Figure 3. Transcription Factors that Differentiate EBV Super-Enhancers from EBV Typical Enhancers
(A) TF motifs enriched at EBV super-enhancers over other control enhancers. Other control enhancers have more than one EBV TF or NF-kB subunit but fewer
than all nine.
(B) Boxplots of TF ChIP-seq signals density at EBV super-enhancers and typical enhancers. Signals for NFAT, STAT5, YY1, and ETS1 at EBV super-enhancers
are significantly higher than typical enhancers (Wilcoxon rank-sum test p values for the following: NFAT, p < 23 1016; STAT5, p < 23 1016; YY1, p < 13 1014;
and ETS1, p < 3.8 3 106; asterisk indicates p < 106).
(C) Anchor plots of normalized TF ChIP-seq signals (coverage) around EBV super-enhancers and EBV typical enhancers.
(D) Boxplots of EBNA2, RBPJ, and EBNA3A ChIP-seq signals (density) at EBV super-enhancers and typical enhancers. EBNA2 and RBPJ ChIP-seq signals at
EBV super-enhancers are significantly higher than EBV typical enhancers (Wilcoxon rank-sum test p values are as follows: EBNA2, p < 7.3 3 1012; RBPJ, p <
1.4 3 1010; EBNA3A, p < 0.019). For boxplots, middle line indicates the median. The edges indicate the first and the third quartile. The whiskers indicate
minimum and maximum.using RNA-seq data from three different LCLs that have min-
imal EBV replication (Arvey et al., 2012; Montgomery et al.,
2010). Super-enhancer-associated genes were expressed at
significantly higher levels than typical enhancer-associated
genes (Wilcoxon rank-sum test, p < 33 1010) (Figure 4). Further-
more, EBV super-enhancer-associated gene expression levels
and typical enhancer-associated gene expression levels
were significantly higher than other control enhancer-asso-
ciated gene expression levels (Wilcoxon rank-sum test, p < 2 3
1016).
H3K27ac Signals at EBV Super-Enhancer Sites in LCLs
and RBLs Have Similar Patterns
Previous analyses of LCL and RBL H3K4me1 signals at EBNA2
sites indicated that EBNA2 sites in LCLs and RBLs have remark-210 Cell Host & Microbe 17, 205–216, February 11, 2015 ª2015 Elseably similar patterns, although LCLs in general have higher
H3K4me1 signals than RBLs (Zhao et al., 2011b). We therefore
analyzed tonsil RBL H3K27ac signals (Chapuy et al., 2013) at
EBV super-enhancer sites. Interestingly, in RBLs, these sites
also had elevated H3K27ac signals, as compared with
neighboring genomic regions. However, RBL H3K27ac signals
were 50% lower than LCL signals (Figure 5A). The elevated
RBL H3K27ac signals are indicative of pioneering B cell TF
occupancy at these sites. Recruitment of p300, CBP, and
PCAF histone acetyl transferases (HAT) or other chromatin
remodeling proteins by EBV and EBV activated TFs such
as EBNA2, EBNA3C, and NF-kB subunits may contribute
to the increased H3K27ac signals (Perkins et al., 1997; Subra-
manian et al., 2002; Wang et al., 2000; Wu et al., 1996).
Other control enhancers with less than all nine EBV TFsvier Inc.
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Figure 4. EBV Super-Enhancer-Associated Genes Have Higher
Expression Levels Than Typical Enhancer-Associated Genes
Boxplots of LCL EBV super-enhancer-associated, EBV typical enhancer-
associated, and other control enhancer-associated RNA-seq gene expression
levels (fragments per kilobase of exon per million fragments mapped [FPKM])
are shown. EBV super-enhancer-associated genes are expressed significantly
higher than EBV typical enhancer-associated genes (Wilcoxon rank-sum test
p < 3 3 1010). EBV super-enhancer-associated genes or EBV typical
enhancer-associated genes are expressed significantly higher than other
control enhancer-associated genes (Wilcoxon rank-sum test p < 2 3 1016).
Middle line indicates the median. The edges indicate the first and the third
quartile. The whiskers indicate minimum and maximum.
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(CE) are shown.
(B) Overlap between RBL, LCL, and EBV super-enhancer-associated genes.
Genes important for B cell or LCL functions are indicated.had much lower H3K27ac signals in both LCLs and RBLs
(Figure 5A).
LCL and RBL Super-Enhancers
To compare LCL super-enhancers with RBL super-enhancers
and identify super-enhancers in LCLs that are not co-occupied
by all EBV TFs, tonsil RBL H3K27ac (Chapuy et al., 2013)
and ENCODE GM12878 LCL H3K27ac ChIP-seq data were
analyzed. The algorithm used to identify EBV super-enhancers
identified 1,756 RBL and 655 LCL super-enhancers (Figures
S2A and S2B). RBL super-enhancers were associated with
most B cell-specific TFs or TFs important for B cell functions.
These included EBF, IKZF1/Ikaros, TCF3/E2A, PAX5, PRDM1/
BLIMP1, IKZF3, OCAB, SPI1/Pu.1, IRF8/ICSBP, RUNX1/3,
and FoxP1. MYC had a super-enhancer at a MYC exon in
RBLs (Figures 5B, S2A, and S2B). Of LCL super-enhancers,
375 (57.3%) also overlapped with RBL super-enhancers. These
included PAX5, IRF8, RUNX3, PRDM1, IKZF3, and OCAB.
LCLs lost the MYC exon super-enhancer. Instead, LCLs
gained two super-enhancers >400 kb upstream of MYC.
LCLs also gained a super-enhancer at MIR155. The vast major-
ity (97%) of EBV super-enhancers were also LCL super-en-
hancers (Figures S3A–S3C). However, in LCLs, even though
PAX5 and IRF8 were still linked to super-enhancers, they
were not targeted by all EBV TFs. RBL and LCL super-Cell Host &enhancer-associated genes were enriched for B cell functions
(Table S4).
EBV Super-Enhancers Are Sensitive to Perturbation
BRD4 binds to acetylated histone lysine residues and further re-
cruits CyclinT and CDK9 to phosphorylate Pol II and activate
transcription. The BET bromodomain small molecule inhibitorMicrobe 17, 205–216, February 11, 2015 ª2015 Elsevier Inc. 211
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All error bars represent SD.
(A) (Left) Twenty-four hours post-DMSO or 500 nM JQ1 treatment of GM12878
LCLs, MYC mRNA levels were measured using qRT-PCR and normalized to
GAPDH. MYC mRNA levels in DMSO treated cells were set to 1. (Right) CFSE
staining of GM12878 LCLs treated with DMSO or 500 nM JQ1 for 1 or 3 days.
(B) (Left) Normalized MYC and MIR21 RNA levels, in conditional EBNA2 LCLs,
grown under permissive (+) or nonpermissive () conditions for EBNA2
expression. (Right) H3K27ac levels at the 525 kb MYC and MIR21 EBV
super-enhancers, as determined by ChIP qPCR. EBNA2 (+) condition was set
to 1.
(C) EBV super-enhancers associate with RUNX3,MIR21, andMIR155. Super-
enhancers are highlighted by red lines with TFs signals indicated on the left.
(D) (Left) Normalized BCL2, RUNX3, and MIR155 mRNA levels in LCLs with
high NF-kB activity (hi) versus low NF-kB activity (lo). (Right) H3K27ac ChIP
qPCR at BCL2, RUNX3, and MIR155 EBV super-enhancers. The NF-kB hi
condition was set to 1.
212 Cell Host & Microbe 17, 205–216, February 11, 2015 ª2015 ElseJQ1 specifically blocks BRD4 binding to acetylated lysine (Fili-
ppakopoulos et al., 2010) and hence disrupts DLBCL super-
enhancer activity (Chapuy et al., 2013). Since BRD4 signals
were evident at EBV super-enhancers and JQ1 disruption has
been a super-enhancer hallmark (Figures 1B and 2D), the effect
of JQ1 treatment on EBV super-enhancer activity was tested.
GM12878 LCLs were treated with 500 nM JQ1 or DMSO vehicle
for 24 hr. MYC expression was evaluated by quantitative RT-
PCR. JQ1 treatment reduced MYC expression by more than
60% (p < 0.004) (Figure 6A). JQ1 treatment also halted LCL
growth, as indicated by carboxyfluorescein diacetate, succini-
midyl ester (CFSE) staining (Figure 6A), indicating that EBV su-
per-enhancers are similar to cell super-enhancers in sensitivity
to BRD4 inhibition.
LCLs transformed by a recombinant EBV that express a
conditional EBNA2, grow normally under permissive conditions
for EBNA2 expression (Zhao et al., 2006). When these LCLs
are grown under nonpermissive conditions for EBNA2, EBNA2
levels decrease and LCLs enter growth arrest (Zhao et al.,
2006). Using these LCLs, we found MYC and MIR21 RNA
levels were reduced by 60%–70% at 72 hr after EBNA2 inacti-
vation (p < 0.0005). Concurrently, ChIP-qPCR found MYC and
MIR21 super-enhancer H3K27ac signals were also significantly
reduced (p < 0.05) (Figure 6B).
Likewise, all NF-kB subunits were evident at BCL2, RUNX3,
and MIR155 super-enhancers (Figures 2D and 6C). Induction
of a conditional IkBa dominant-negative mutant in LCLs inacti-
vates NF-kB (Cahir-McFarland et al., 2000). NF-kB inactivation
resulted in an 50%–80% reduction in BCL2, RUNX3, and
MIR155 gene expression (p < 0.0005) and caused a 40%–
80% reduction in H3K27ac signals at BCL2, RUNX3, and
MIR155 EBV super-enhancer sites (p < 0.05) (Figure 6D).
Furthermore, basal promoter luciferase reporters under the con-
trol of four different EBV super-enhancers or three different EBV
typical enhancers were transfected into these LCLs. Luciferase
activities were determined in LCLs with wild-type or reduced
NF-kB activity. Inactivation of NF-kB reduced super-enhancer
reporter activity bymore than 40%and typical enhancer reporter
activity by less than 20% (p < 0.02) (Figure S4), indicating that
EBV super-enhancers were more sensitive to NF-kB inactivation
than EBV typical enhancers.
DISCUSSION
B cell-specific tissue imprinting and associated TFs maintain B
cell precursors in the bone marrow. EBF expression and pio-
neering effects of other B cell lineage TFs, IKZF1, SPI1, and
PAX5, coordinately establish mature B cell identity and control
gene expression (Lin et al., 2010). Subsequent antigen binding
to B cell receptors and T cell CD40 ligand stimulation mediate
RBL transcription activation.
During primary EBV infection, EBV transforms B cells into
proliferating blasts, some of which ultimately differentiate into
memory B cells. Latent EBV infection of the B cell compart-
ment enables lifelong EBV infection. EBV-infected B cells
can cause lymphomas in immune-suppressed individuals.
This phenomenon is recapitulated in vitro, where EBV
oncoprotein expression converts RBLs into LCLs. Our data
indicate that EBV evolved to usurp B cell-intrinsic programsvier Inc.
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Figure 7. EBV Super-Enhancer Model
RBLs have broad enhancer regions with moderate H3K27ac signals. These
enhancers are occupied by a limited repertoire of cell TFs to maintain chro-
matin accessibility. Upon EBV infection, EBNA and LMP1 oncoproteins are
expressed. LMP1 activates NF-kB. All EBNAs and NF-kB subunits then co-
occupy primed B cell enhancer sites, recruit additional cell TFs, and nucleate
EBV super-enhancers to upregulate transcription.to support rapid growth and survival of latently infected B cells
(Figure 7).
We herein identify a class of EBV super-enhancers that are
comprised of EBV-encoded, EBV-activated, and EBV-associ-
ated B cell TFs. These EBV super-enhancers have exception-
ally high signals for activation-associated histone modifica-
tions, Pol II, and chromatin remodeling factors, indicative of
highly active transcription. EBV super-enhancers were associ-
ated with EBF, a principal pioneering B cell lineage factor,
which increases chromatin accessibility, STAT5 and NFAT,
which may nucleate EBV super-enhancer formation. These
EBV super-enhancers likely exploit their high YY1 binding to
loop to the TSS of affected genes, including genes critical for
B cell growth and survival. EBV super-enhancers were sensitive
to BRD4 perturbations as well as to EBNA2 and NF-kB
inactivation.
EBV efficiently transforms RBLs within a week after infection.
Thereafter, infected RBLs replicate every 24 hr, in vitro (Nikitin
et al., 2010). Similarly, EBV-infected cells can replicate continu-
ously in immune-deficient humans and express the same EBV
genes as LCLs (Young et al., 1989). The convergence of all
the EBV oncoproteins and EBV activated NF-kB subunits atCell Host &EBV super-enhancers has now been dynamically demonstrated
to be a key determinant of continuous LCL growth.
EBNA2 is the principal EBV super-enhancer component
that upregulates MYC. MYC overexpression is frequently the
result of distal strong enhancers that loop to the MYC TSS.
In prostate, breast, and colon cancers, the 8q24 cancer risk
variant rs6983267, which is 335 kb from MYC TSS, preferen-
tially binds TCF7L2 and loops to MYC (Pomerantz et al., 2009).
Similarly, EBNA2 mediates looping from a 428 kb MYC
enhancer to MYC (Zhao et al., 2011b). Another EBV super-
enhancer which is 525 kb upstream of MYC is also likely
to affect MYC activation. A long noncoding RNA 515 kb up-
stream of MYC can also loop to the MYC rs6983267 enhancer
and affect enhancer activity (Xiang et al., 2014). Therefore,
MYC expression is complex, and likely involves multiple distinct
super-enhancers.
MYC overexpression-induced cell cycle entry causes
apoptosis in the absence of strong prosurvival effects from
BCL2 or activated tyrosine kinase growth factor receptors.
EBV-associated Burkitt’s lymphomas overexpress MYC as
a consequence of chromosome translocations placing MYC
under control of strong immunoglobin enhancers. To overcome
MYC-induced apoptosis, p53 is mutated in >50% of Burkitt’s
lymphomas, and B cell lymphomas in MYC transgenic mice
also often have inactivated p53 or ARF (Eischen et al., 1999;
Love et al., 2012). In LCLs, two EBV super-enhancers upregulate
BCL2 expression and thereby prevent MYC-induced apoptosis
in LCLs. Lymphomas with both MYC and BCL2 overexpression
have very poor clinical outcomes (Hu et al., 2013).
EBV infection of primary B cells upregulates MIR155, MIR21,
and LET7I, which are important for LCL growth (Skalsky et al.,
2012). MIR155 is essential for LCL proliferation. EBV super-en-
hancers, enriched with EBNA2, EBNALP, and LMP1-activated
NF-kB subunits, upregulate MIR155 and MIR21 expression in
LCLs (Rosato et al., 2012; Yang et al., 2013). MIR21 regulates
PTEN, and LET7I is associated with high-grade lymphomas
(Lawrie et al., 2009). Control of these critical mirRNAs by EBV su-
per-enhancer likely ensures LCL growth and survival.
Chromosome conformation capture carbon copy assays
suggest that as few as 7% of enhancers regulate their nearest
genes, although this can vary substantially among cell types
(Sanyal et al., 2012). In contrast, >90%of super-enhancers affect
their nearest gene by Hi-C (Whyte et al., 2013). In support of
most EBV super-enhancers also regulating the nearest pro-
moter, we found that perturbation of EBV super-enhancers
very frequently reduced expression of the nearest LCL genes
and associated super-enhancer H3K27ac signals. These find-
ings further correlated EBV super-enhancers to their nearby
regulated genes.
Super-enhancers are highly accessible open chromatin re-
gions with multiple co-occurring cell TFs. Although ‘‘accessible’’
loci may be prone to artifacts (Teytelman et al., 2013),
EBV super-enhancers are specifically composed of EBNA2,
EBNALP, EBNA3A, EBNA3C, EBV-activated NF-kB subunits,
and other EBV protein-associated cell TFs, as well as cofactors,
active chromatin regulators, BRD4 and H2AZ, and core TFs. It is
highly unlikely that EBV super-enhancers are due to ChIP-seq
‘‘artifacts,’’ since dynamic perturbation of these super-en-
hancers by conditional EBNA2 or NF-kB inactivation led toMicrobe 17, 205–216, February 11, 2015 ª2015 Elsevier Inc. 213
downregulation of EBV super-enhancer-associated genes and
cessation of cell growth. Furthermore, EBV super-enhancers
are functionally relevant to LCL biology.
EBNA2 inactivation substantially decreased MYC expression,
but had surprisingly little effect on BCL2 expression, whereas
NF-kB inactivation had a dramatic effect on BCL2 expression
and small effect on MYC expression, confirming that MYC and
BCL2 are differentially affected by EBNA2 and NF-kB, respec-
tively. Increased activities from other EBV super-enhancer con-
stituents are likely to compensate for the deficiency. Thus, the
co-occurrence of other EBV TFs and NF-kB subunits at MYC
and BCL2 may be indicative of an underlying, fail-safe transcrip-
tion mechanism that assures proliferation and survival.
Like other super-enhancers (Love´n et al., 2013), EBV super-
enhancers were sensitive to perturbations. JQ1 inhibition
decreased super-enhancer-associated transcription more than
typical enhancer-associated transcription (Chapuy et al., 2013;
Love´n et al., 2013). As reflected in BRD4 inhibition and EBNA2
and NF-kB inactivation, EBV super-enhancers were sensitive
to perturbation. These data indicate that EBV super-enhancer
disruption may be effective in controlling EBV-transformed cell
growth.
EXPERIMENTAL PROCEDURES
Sequencing Data Alignment
All ChIP-Seq reads were mapped to hg19 using Bowtie (version 0.12.9). Align-
ments were done with parameters: -S -t -p 1 -k 1 -m 1.
Identifying ChIP-Seq-Enriched Regions
MACS (1.4.2) was used to identify ChIP-seq TF binding sites. Default param-
eters were used with the exception of ‘‘to-large,’’ which was set due to low
sequencing depth of older ChIP-seq data sets.
Motif Enrichment
HOMER (4.4) ‘‘findMotifsGenome.pl’’ was used to identify enriched motifs
(Heinz et al., 2010) with ‘‘other control enhancers’’ set as background.
Identification of Overlapping Binding Sites
HOMER ‘‘MergePeak’’ was used to identify the co-occurrence of binding sites
(default parameters). If there was an overlap between the start and end coor-
dinates of both enhancer regions, these enhancers were considered
‘‘overlapping.’’
Definition of EBV Enhancers
EBV enhancers were defined by the colocalization of four EBNAs and five NF-
kB subunits. Binding sites of these transcription factors were identified by
MACS. ‘‘Other control enhancers’’ were defined by the presence of at least
one, but less than all nine, TFs.
Identifying EBV Super-Enhancers and EBNA2 Super-Enhancers
To identify EBV super-enhancers, all EBV enhancers were ranked according to
their total background-subtracted H3K27ac ChIP-seq signal. EBV enhancers
were sorted and plotted based on H3K27ac signals in ascending order. The
x axis shows H3K27ac ChIP-seq signals’ rank order; the y axis shows normal-
ized H3K27ac signals. A line was drawn from the first enhancer with lowest
signal to the last enhancerwith the highest signal to determine adiagonal slope.
A point on the ranked plot with a tangent line identical to the diagonal slopewas
identified. This x axis point was set as the cutoff to distinguish EBV super-en-
hancers fromEBV typical enhancers. TheEBVenhancerswithH3K27acsignals
higher than this point were assigned as EBV super-enhancers.
EBNA2 super-enhancers were identified as described above using EBNA2
ChIP-seq signals. EBNA2 binding sites within 12.5 kb were stitched together
as previously described (Whyte et al., 2013).214 Cell Host & Microbe 17, 205–216, February 11, 2015 ª2015 ElseHi-C Validation of Super-Enhancer, and Associated Gene
Assignment
GM12878 LCL Hi-C topological association domains (generated by Bing Ren
Lab) (Selvaraj et al., 2013) were used to validate the assignment of super-
enhancer and associated gene pairs. Correct assignments were scored based
on the co-occurrence of a super-enhancer and its associated gene within the
same TAD.
Anchor Plots
Anchor plots show the distribution of TFs and histone modification ChIP-
Seq signals at various binding sites, as previously described (Portal et al.,
2013).
Gene Expression Analysis
EBV super-enhancer-, EBV typical enhancer-, and EBV other control
enhancer-associated gene expression was determined using LCL RNA-seq
data. The average gene expression level (FPKM) was calculated with three
LCLs (NA06985, NA07000, and NA07347). RNA-seq data from these three
LCLs were chosen because they had the least amount of EBV late gene
expression. Boxplots were drawn using R, and the statistical significance of
the difference between each two pairs of the three groups was determined
using the Wilcoxon signed-rank test.
Pathway Enrichment Analysis
The enriched pathways of super-enhancer-associated genes were identified
using the ‘‘Identify Pathways’’ function of the IntPath database (Zhou et al.,
2012) and DAVID database (Huang et al., 2008).
Reporter Assays
Four EBV super-enhancer and three typical enhancer sequences were
PCR amplified and cloned into pGL3 promoter luciferase reporter vectors
(Promega). A total of 20 mg of control or enhancer luciferase vectors,
together with 2 mg of Renilla expression vector, was electroporated
(Gene Pulser II, Bio-Rad), into 7 3 106 LCLs containing an inducible
IkBa mutant. Electroporated cells were split into permissive or nonpermis-
sive conditions for mutant IkBa expression and grown for 48 hr. Dual lucif-
erase/Renilla assays were done following the manufacturer’s directions
(Promega).
ACCESSION NUMBERS
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